Zydus Lifesciences Q3 FY26 results: Consol revenue up 30%, PAT flat

Revenue Growth 20pctRevenue DeclineExceptional ItemResults View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹887.00

prior close

₹908.25

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.7%+3.2% vs market

Pharmaceuticals peers, median of 159sector+1.8%+2.2% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty 100 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+2.4

15m

+1.3

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9+0.7+3.2+1.8+2.2

Next day

+0.0+1.0-1.0+2.4-2.4

+1.4+1.1+0.2+2.0-0.7

+3.7+0.6+3.1+1.2+2.5

+2.2-0.8+3.0+0.7+1.5

+2.6+0.1+2.5+0.0+2.6

+2.9+0.7+2.2+0.7+2.1

15d

+2.1-2.8+4.9-4.4+6.4

+2.4-6.1+8.5-5.3+7.6

+1.6-6.9+8.5-3.0+4.5

+8.2-5.8+14.0+4.6+3.6

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences posted Q3 FY26 consolidated revenue of Rs 68,645 million, up 30% YoY driven by new acquisitions Amplitude Surgical and Comfort Click. Net profit was nearly flat at Rs 10,421 million vs Rs 10,235 million. Standalone revenue fell 9% YoY to Rs 22,836 million with PAT at Rs 2,965 million vs Rs 4,706 million, hit by a one-time Labour Codes charge of Rs 601 million. Auditor Deloitte issued an unmodified limited review report.

Likely market impact

Strong consolidated growth from acquisitions offsets weak standalone performance and exceptional charge. Mixed picture for shareholders.